Year Founded
2015
Ownership
Private
Employees
~10
Therapeutic Areas
OtherDermatology
Stage
Commercial
Modalities
Bioengineered tissueBioprinting

Jellagen General Information

Company has developed a jellyfish-derived Collagen Type 0 platform for tissue engineering and regenerative medicine applications. Their product JellaGel is commercially available for research use.

Contact Information

Website
Primary Industry
[ "Biotech", "Medical Devices", "CDMO" ]
Corporate Office
Cardiff, Wales
United Kingdom

Drug Pipeline

JellaGel
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Jellagen's pipeline data

Book a demo

Key Partnerships

National Physical Laboratory

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Jellagen Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Jellagen's complete valuation and funding history, request access »

Jellagen Investors

Thai Union Corporate Venture Capital Fund
Investor Type: Venture Capital
Holding: Minority